Leadership
Coloplast has a two-tier management structure, comprised of a Board of Directors and an Executive Leadership Team. Together, they have the skills, experience and expertise to lead the company effectively and represent the views of our stakeholders.
(FY 2023/24)
Board evaluation – annual self-assessment (FY 2023/24)
Every year, the Board of Directors conducts a self-assessment. Based on the result of this assessment, the organisation and efficiency of the Board of Directors' work are discussed at a Board meeting.
In 2024, the annual self-assessment of the Board of Directors was performed partly with external assistance. The self-assessment consisted of 74 questions in which board members as well as the Executive Leadership Team responded anonymously.
The self-assessment shows that there is an open and transparent dialogue between the Board of Directors and the Executive Leadership Team, and the board committees serve as good vehicles for framing the discussions in the Board of Directors and ensure that key risks are addressed.
Furthermore, the self-assessment shows that the composition of the Board of Directors, including relevant competencies, matches what the Board of Directors considers necessary to best perform its tasks, such as finance, digital transformation, customer experience, commercialisation, sustainability, industry knowledge incl. the US market, general management, innovation, legal affairs and acquisitions. However, as part of the upcoming strategy process the Board of Directors will discuss which competencies are needed to deliver on the next strategy.
During the past year, the Board of Directors has spent time monitoring and discussing the progress made on Coloplast’s Strive25 strategy as well as the performance and integration of Kerecis hf.. Furthermore, the Board of Directors has spent a significant amount of time discussing and addressing challenges caused by current world events.